lymphomas

Elimusertib (BAY-1895344) is a potent, highly selective, and orally available ATR inhibitor with an IC50 of 7 nM, demonstrating significant anti-tumor efficacy as a monotherapy and strong combination potential with targeted alpha therapy Radium-223 dichloride.

Cyclophosphamide is an alkylating agent type of anti-tumor drug, and its main target is DNA. Cyclophosphamide inhibits the proliferation of tumor cells by undergoing alkylation reactions with DNA, interfering with the replication and transcription processes of DNA.

(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.

PG-11047 2HCl is an apoptosis-stimulating agent used in the treatment of genitourinary disorders, immune system disorders, genetic disorders and malformations, ocular disorders, and disorders of the blood and lymphatic systems, and in the study of lymphomas and prostate cancer.

Imofinostat (MPT0E028) is a selective, orally available pan-HDAC inhibitor with IC₅₀ values of 53.0/106.2/29.5 nM against HDAC1/HDAC2/HDAC6 in HCT116 cells. In B-cell lymphoma, Imofinostat induces cell cycle arrest and apoptosis whilst inhibiting Akt phosphorylation, demonstrating anticancer activity across multiple tumour types.

Vincristine sulfate is an alkaloidal natural product that binds to microtubule proteins and inhibits the formation of microtubules, thereby inhibiting mitosis in tumor cells. Vincristine sulfate is used as a microtubule destabilizing agent in research studies for the treatment of hematologic neoplasms such as leukemias and lymphomas, as well as in studies related to sarcomas in children.

Forodesine (BCX-1777) is an orally active and potent purine nucleoside phosphorylase (PNP) inhibitor, a new purine nucleoside analog, inhibitor of human lymphocyte proliferation, induces apoptosis in leukemic cells by increasing dGTP levels, and may be useful in the study of cutaneous T-cell lymphomas.

QL47 is a host-targeted small molecule antiviral agent with antiviral activity against dengue and other RNA viruses.QL47 acts as an inhibitor of viral translation and a covalent inhibitor of BTK, and can be used in the study of lymphomas.

Lenalidomide-6-F-piperidine-C2-Pip-C-COOH acts as a linker and an E3 ligase ligand for PROTACBTKDegrader-5, utilized in the study of malignant lymphomas.

Lonitoclax is an inhibitor of B-cell lymphoma 2 (Bcl-2). It demonstrates antitumor activity in B-cell and myeloid malignancy models comparable to Venetoclax. Lonitoclax holds potential for research in relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas.

BMS-986238 is a second-generation macrocyclic peptide and an effective PD-L1 inhibitor. It holds potential for research in the treatment of solid tumors and lymphomas (cancer of the lymphatic system).

Aclacinomycin A (Aclarubicin) is a novel anthracycline antibiotic isolated from Streptomyces galilei with antitumor activity.Aclacinomycin A is an inhibitor of topoisomerases I and II and inhibits RNA activity.Aclacinomycin A has been used in the study of relapsed leukemia and advanced malignant lymphomas.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

Cellocidin is a potent gammaherpesvirus-associated B-lymphomas growth inhibitor. It acts through the activation of both the NF-κB and c-Myc-mediated signaling pathways.

NSC10010 hydrochloride is an effective growth inhibitor for gammaherpesvirus-associated B-lymphomas. It acts through activation of both the NF-κB and c-Myc-mediated signaling pathways.

BC-23 (NSC 45382) is a potent proteasome inhibitor with antitumor and antimicrobial activity, inhibiting the CT-L activity of the proteasome and used in the study of leukemias, lymphomas, gliomas, breast cancer, and small cell lung cancer.

AZD5153 is a reversible inhibitor of BRD4, a bromodomain and extra-terminal family protein, with antitumor activity.AZD5153 inhibits hepatocarcinogenesis by altering the BRD4 chromosome landscape and regulating the transcriptome of HCC cells.AZD5153 is used in the study of lymphomas and solid tumors.

DMBA (7,12-Dimethylbenz[a]anthracene) is a carcinogenic polycyclic aromatic hydrocarbon (PAH) that can be used to induce animal models of leukemia, liver cancer, breast cancer, skin cancer, and lung cancer. It is also capable of inducing programmed cell death (apoptosis) in A20.1 murine B-cell lymphoma.

Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and

5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450) and a metabolite of Xanthotoxin. It is used in the treatment of psoriasis, eczema, vitiligo, and certain cutaneous lymphomas in combination with phototherapy involving exposure to sunlight.

Tubulin polymerization-IN-36 is able to be used in cancer research, for example, lymphomas. Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding, that is an inhibitor of tubulin polymerization with IC50 of 2.8 μΜ[1].

Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 µM) of tubulin polymerization, binding specifically to the colchicine site of tubulin and preventing colchicine binding, with potential applications in cancer research, notably for lymphomas [1].

KC-11404 is an LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor and 5-lipoxygenase.

CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.